• Date: March 08, 2018

The Barcelona company ABAC Therapeutics has closed a Series A financing round worth 16 million euros. Specialised in discovering new antibiotics to combat multidrug-resistant bacteria, ABAC plans to allocate these funds to bring its anti-Acinetobacter baumanii programme to the clinical trial phase.

The aforementioned bacterium is a frequent cause of hospital infections, and it tops the list drawn up by the World Health Organisation of pathogens that urgently require new treatments.

Caixa Capital Risc was one of the participants in this round of financing, together with the Pontifax fund, the Global Health Science Fund, the Debiopharm Innovation Fund and the pharmaceutical company Ferrer.

More news

December 18, 2018

The use of Big Data to improve healthcare, at the EIT Health Summit

The EIT Health Summit, held on 4-5 December in Łódź (Poland), brought together over 400 experts in medical innovation from all over Europe.

November 29, 2018

Applications open for the LCF Health Research programme

”La Caixa” Banking Foundation (LCF) has launched the second edition of the open call for Health Research projects, which will remain open until 15 January.

November 27, 2018

Open call for innovative start-ups to participate in the EntrepreneurXXI Awards

Highly innovative start-ups and SMEs from Spain and Portugal are invited to apply for the EntrepreneurXXI Awards until 12 December.